AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15212190
Drug: Tulobuterol TTS
RxNorm normalized name: tulobuterol
DrugBank: Tulobuterol (DB12248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tulobuterol TTS (Hokunalin Tape) without inhalational steroids
Trial: 15212190
Drug: Inhalational steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalational steroids
Trial: 11769150
Drug: FPD patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPD patch
Trial: 2427411
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received the infusion solution and vasodilator drugs
Trial: 30766594
Drug: 100 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 µg oral clonidine pre‐medication
Trial: 30766594
Drug: 200 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 µg oral clonidine pre‐medication
Trial: 30766594
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no oral clonidine pre‐medication)
Trial: 23756400
Drug: Shiitake mushroom
RxNorm normalized name: Shiitake Mushroom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shiitake mushroom extract (700 mg, two times per day)
Trial: 20653494
Drug: Olanzapine orodispersible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine orodispersible tablet (ODT)
Trial: 20653494
Drug: Oral conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral conventional tablet (OCT)
Trial: 18408938
Drug: Pethidine 1
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine 1 mg/kg (Group I, n = 60)
Trial: 18408938
Drug: Tramadol 2
RxNorm normalized name: traMADol 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 2 mg/kg (Group II, n = 50)
Trial: 14555299
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (SCG) 2 mg four times daily
Trial: 19549432
Drug: CIC treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIC treatments (all groups)
Trial: 16401531
Drug: Training and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training and Support Programme (TSP) - 8 weekly sessions, 1 hour each, teaching massage skills
Trial: 15253580
Drug: Control (Conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Conventional treatment)
Trial: 8104272
Drug: Regular inhaled
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular inhaled salbutamol (200 micrograms four times daily for 2 weeks)
Trial: 3769482
Drug: DHPA 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHPA 150 mg + E2‐EN 10 mg (group I, n = 9)
Trial: 3769482
Drug: Half-dose of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose of DHPA + E2‐EN (group II, n = 7)
Trial: 27297013
Drug: Routine iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine iron prophylaxis (60 mg ferrous sulfate plus 400 μg folic acid daily)
Trial: 27297013
Drug: Selective iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective iron prophylaxis (1 mg folic acid daily and Hb screening with treatment for low Hb)
Trial: 24980710
Drug: Extended therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended therapy (72 weeks of PEG‐IFNα‐2a)
Trial: 24980710
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (48 weeks of PEG‐IFNα‐2a)
Trial: 15948808
Drug: 10-day sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day sequential therapy (rabeprazole 20 mg b.d. plus amoxicillin 1 g b.d. for the first 5 days, followed by rabeprazole 20 mg, clarithromycin 500 mg and tinidazole 500 mg, all b.d., for the remaining 5 days)
Trial: 15948808
Drug: Standard 7-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 7-day triple regimen (rabeprazole 20 mg, clarithromycin 500 mg and amoxicillin 1 g, all b.d.)
Trial: 6615689
Drug: Meptazinol 400
RxNorm normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meptazinol 400 mg
Trial: 6615689
Drug: Pentazocine 100
RxNorm normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentazocine 100 mg
Trial: 26681132
Drug: Cocoa flavanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa flavanol (CF) ingestion (900 mg CF per study day)
Trial: 24716412
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment + rhBNP (recombinant human B-type natriuretic peptide) for up to 7 days
Trial: 19237881
Drug: Hemofiltration (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemofiltration (25 mL/kg/hr) for a 96-hour period
Trial: 15689054
Drug: Novel polyherbal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel polyherbal formulation (PF; Aller‐7/NR‐A2)
Trial: 11705489
Drug: Imatinib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib at a dose of 500 mg twice daily
Trial: 11705489
Drug: Imatinib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib at a dose of 400 mg twice daily
Trial: 7993413
Drug: Intravenous dobutamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dobutamine (5 to 200 micrograms per kilogram of body weight per minute)
Trial: 7993413
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (dobutamine administered only if cardiac index was below 2.8 liters per minute per square meter)
Trial: 3281701
Drug: Clonidine 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 0.6 mg by mouth 2 h before operation
Trial: 29453232
Drug: Docosahexaenoic acid
RxNorm normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docosahexaenoic acid (DHA) 1,000 mg by mouth twice daily for 12 weeks
Trial: 23833564
Drug: Ipilimumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (10 mg/kg IV every 3 weeks for up to 4 doses)
Trial: 23833564
Drug: Dacarbazine (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacarbazine (850 mg/m2 IV every 3 weeks)
Trial: 23833564
Drug: Carboplatin/paclitaxel (Paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin/paclitaxel (Paclitaxel 175 mg/m2 IV and Carboplatin [AUC=6] IV every 3 weeks)
Trial: 23833564
Drug: Ipilimumab maintenance
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab maintenance (10 mg/kg every 12 weeks)
Trial: 11583471
Drug: ketoconazole (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketoconazole (three 200 mg doses spaced 12 hours apart)
Trial: 1099860
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg diazepam intravenously as preoperative sedative
Trial: 15175486
Drug: Verbal descriptors
RxNorm normalized name: delavirdine mesylate Oral Tablet [Rescriptor]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verbal descriptors (e.g., 'common' for constipation, 'rare' for pancreatitis)
Trial: 15175486
Drug: Numerical descriptors
RxNorm normalized name: delavirdine mesylate Oral Tablet [Rescriptor]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Numerical descriptors (e.g., 2.5% for constipation, 0.04% for pancreatitis)
Trial: 11672493
Drug: Dexamphetamine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamphetamine (up to 60 mg daily)
Trial: 11672493
Drug: Counselling (weekly)
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Counselling (weekly)
Trial: 30318837
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (0.3 g·kg‐1 body mass)
Trial: 30318837
Drug: Placebo (maltodextrin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (maltodextrin, 0.2 g·kg‐1 body mass)
Trial: 18303254
Drug: Clopidogrel plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel plus aspirin (75 mg/day plus 75-162 mg/day)
Trial: 16291412
Drug: Topical ketotifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ketotifen fumarate 0.025% ophthalmic solution
Trial: 16291412
Drug: Topical olopatadine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical olopatadine HCl 0.1% ophthalmic solution
Trial: 12145231
Drug: Sildenafil 25
RxNorm normalized name: sildenafil 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 25 mg (acute effect)
Trial: 12145231
Drug: Sildenafil 25
RxNorm normalized name: sildenafil 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 25 mg (prolonged effect after 2 weeks)
Trial: 7614527
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg twice daily, up to 50 mg if needed) plus hydrochlorothiazide (HCTZ)
Trial: 7614527
Drug: Digoxin (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (0.1 mg twice daily) plus hydrochlorothiazide (HCTZ)
Trial: 2393281
Drug: Cefprozil 250
RxNorm normalized name: cefprozil 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefprozil 250 mg
Trial: 2393281
Drug: Cefprozil 1000
RxNorm normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefprozil 1000 mg
Trial: 2393281
Drug: Cefaclor 500
RxNorm normalized name: cefaclor 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 500 mg
Trial: 57340
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of steroid drugs plus 600 rads of radiotherapy to the graft
Trial: 26220326
Drug: Individually-defined therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individually-defined therapy program (IT)
Trial: 26220326
Drug: General therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General therapy program (GT)
Trial: 19492250
Drug: NT-proBNP level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP level in TOF patients repaired with transannular patch
Trial: 19492250
Drug: NT-proBNP level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP level in TOF patients operated on without transannular patch
Trial: 11108723
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil diet (50 g of oil per 10 MJ)
Trial: 11108723
Drug: Rapeseed oil
RxNorm normalized name: Rapeseed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapeseed oil diet (50 g of oil per 10 MJ)
Trial: 11108723
Drug: Sunflower oil
RxNorm normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunflower oil diet (50 g of oil per 10 MJ)
Trial: 6240210
Drug: atracurium (ATR)
DrugBank: Atracurium (DB13295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: atracurium (ATR) 0.33 mg X kg‐1
Trial: 6240210
Drug: alcuronium (DAN)
RxNorm normalized name: alcuronium
DrugBank: Alcuronium (DB13648)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alcuronium (DAN) 0.1 mg X kg‐1
Trial: 6240210
Drug: succinylcholine (SCH)
DrugBank: Succinylcholine (DB00202)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: succinylcholine (SCH) 1.0 mg X kg‐1
Trial: 30044792
Drug: Anfoleish cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anfoleish cream administered 2 times per day (BID group) for 4 weeks
Trial: 30044792
Drug: Anfoleish cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anfoleish cream administered 3 times per day (TID group) for 4 weeks
Trial: 25546691
Drug: In-plane ultrasound-guided
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-plane ultrasound-guided injection with 40 mg of triamcinolone and 1 mL of 1% lidocaine
Trial: 25546691
Drug: Out-plane ultrasound-guided
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Out-plane ultrasound-guided injection
Trial: 25546691
Drug: In-plane ultrasound-guided
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-plane ultrasound-guided injection
Trial: 17414691
Drug: Open-label, flexible-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label, flexible-dose antidepressant treatment for 8 weeks
Trial: 11931781
Drug: Regimen A
RxNorm normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A (3 weekly injections as induction, followed by injections every 2 weeks)
Trial: 11931781
Drug: Regimen B
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B (two injections at day 1 and day 15 as induction, followed by injections every 4 weeks)
Trial: 10868864
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg)
Trial: 7126418
Drug: Hydrochlorothiazide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (100 mg/day) alone
Trial: 7126418
Drug: Hydrochlorothiazide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (100 mg/day) with spironolactone (100 mg/day)
Trial: 7126418
Drug: Combination therapies
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapies (Hydrochlorothiazide and spironolactone)
Trial: 7126418
Drug: Hydrochlorothiazide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (100 mg/day) once daily
Trial: 25043278
Drug: Low-dose sIPV
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose sIPV
Trial: 31151464
Drug: Oral taurine
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral taurine supplementation
Trial: 28012528
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone 0.5 mg/kg (maximum dose 16 mg)
Trial: 28012528
Drug: Pre‐incision infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre‐incision infiltration of local anesthesia (2-4 ml mixture with saline)
Trial: 28012528
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone 0.5 mg/kg
Trial: 25612858
Drug: Ceftriaxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (2 g every 24 hours for 4 days)
Trial: 19665347
Drug: MI-CBT (Motivational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MI-CBT (Motivational Interviewing + Cognitive Behavioral Therapy)
Trial: 14969576
Drug: Budesonide/formoterol 320/9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol 320/9 microg twice daily
Trial: 11467142
Drug: 2-site regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-site regimen (0.2 ml at 2 sites on days 0, 3, 7; 1 site on days 28, 90)
Trial: 11467142
Drug: 8-site regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-site regimen (0.1 ml at 8 sites on day 0; 4 sites on day 7; 1 site on days 28, 90)
Trial: 9747644
Drug: Plantago Psyllium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plantago Psyllium (5 g t.i.d.)
Trial: 20547600
Drug: Sodium salicylate
RxNorm normalized name: Sodium Salicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium salicylate injections into tender, thickened areas of subcutaneous tissue on the forearm and upper scapular region.
Trial: 20547600
Drug: Sham injections
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injections consisting of pressure without skin penetration.
Trial: 18400140
Drug: Dexmedetomidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.5 microg kg(‐1) administered intravenously over 60 s
Trial: 18400140
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of 0.9% NaCl administered intravenously over 60 s (Control Group)
Trial: 15746991
Drug: Prednisone 5
RxNorm normalized name: prednisone 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 5 mg/day
Trial: 11955844
Drug: Double the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double the ACE inhibitor dose (n = 10)
Trial: 11955844
Drug: Add an
RxNorm normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Add an angiotensin II antagonist (n = 10)
Trial: 11955844
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (n = 10)
Trial: 10206072
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with Mitoxantrone, methotrexate (+/‐ mitomycin C), and tamoxifen for four 3‐weekly cycles
Trial: 10206072
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with Mitoxantrone, methotrexate (+/‐ mitomycin C), and tamoxifen
Trial: 10206072
Drug: Non-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-treatment control group (20 patients)
Trial: 2079058
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate 0.5 g.kg‐1 body mass
Trial: 7418568
Drug: Daily regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily regimen of isoniazid (INH) plus rifampicin (RMP) plus ethambutol (EMB)
Trial: 7418568
Drug: Twice-weekly regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly regimen of isoniazid (INH) plus rifampicin (RMP) plus ethambutol (EMB)
Trial: 7418568
Drug: Daily regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily regimen of isoniazid (INH)
Trial: 7418568
Drug: Twice-weekly regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly regimen of rifampicin (RMP)
Trial: 28369299
Drug: Pentasa® enemas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentasa® enemas 25 mg/kg (up to 1g) daily for 3 weeks
Trial: 22882430
Drug: Oral desensitization
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral desensitization with raw hen's egg starting from 0.27 mg (1 drop diluted 1:100) and increasing doses over 6 months
Trial: 20727238
Drug: Gold kiwifruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold kiwifruit with iron-fortified breakfast cereal (16 mg Fe as ferrous sulfate) and milk
Trial: 20727238
Drug: Banana with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Banana with iron-fortified breakfast cereal (16 mg Fe as ferrous sulfate) and milk
Trial: 11447381
Drug: Rofecoxib (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (12.5 mg, 25 mg)
Trial: 9738560
Drug: Control (antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (antibiotics only)
Trial: 30223903
Drug: Blended GP
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended GP educational programme (online and face-to-face training) with proactive discussion of pain management and prescription of paracetamol and ibuprofen according to guidelines.
Trial: 25771087
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) administered subcutaneously
Trial: 25771087
Drug: Acenocoumarol (Vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acenocoumarol (Vitamin K antagonist)
Trial: 23064902
Drug: Glutamine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine (15 g orally, three times daily)
Trial: 18341663
Drug: Methyl aminolaevulinate-photodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyl aminolaevulinate-photodynamic therapy (MAL-PDT)
Trial: 17065974
Drug: Antidepressant selection
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant selection based on drug factors (tolerability, interactions, cost), depression subtype, psychiatric and medical comorbidity, and stage of life.
Trial: 17065974
Drug: Patient preference
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient preference for avoiding certain side effects and personal and family history of treatment response.
Trial: 11121910
Drug: 5-day regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-day regimen with rabeprazole 10 mg b.d., clarithromycin 400 mg b.d. and amoxicillin 750 mg b.d.
Trial: 11121910
Drug: 7-day regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 7-day regimen with rabeprazole 10 mg b.d., clarithromycin 400 mg b.d. and amoxicillin 750 mg b.d.
Trial: 1350367
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of sodium cromoglycate